Abstract: 【Abstract】Objective To observe the efficacy and safety of sodium thiosulfate (STS) in the treatment of uremic pruritus. Methods Sixty patients with uremic pruritus were randomly divided into observation group (n=30) and control group (n=30). The control group was given loratadine 10mg orally once daily, and the observation group was given STS 3.2g intravenously three times a week after dialysis in addition to the loratadine treatment in control group. They were observed for 3 months. The changes of inflammatory index, modified Duo's pruritus score, Pittsburgh sleep quality index (PSQI) score and the incidence of adverse reactions were compared before and after the treatment. Results The total clinical effective rate was 96.70% in the observation group, significantly higher than that (63.30%) in the control group (χ2=10.892, P=0.001). The changes of C- reactive protein (t=15.170, P<0.010), ferritin (t=7.330, P<0.010) and albumin (t=- 9.030, P<0.010) before and after treatment were statistically significant in the observation group; however, the changes of C-reactive protein (t=1.170, P=0.055) and ferritin (t=1.731, P=0.086) before and after treatment did not have statistical significances in the control group. Modified Duo score (intra-group: t=14.480, P<0.001; intergroup: t=- 11.220, P<0.001) and PSQI score (intra- group: t=33.240, P< 0.001; inter- group: t=- 14.480, P<0.001) after the treatment were significantly lower than those before the treatment in the observation group and were also lower than those before treatment in the control group. There was no significant difference in
the incidence of adverse reactions between the two groups (χ22=0.218, P=0.640). Conclusions STS combined with anti-allergic therapy is more effective in the treatment of uremic pruritus without serious adverse reactions.

Key words: Sodium thiosulfate, Maintenance hemodialysis, Uremic pruritus